Abstracts tagged "Scleroderma"

Abstract Number: 2493 • ACR Convergence 2025
Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
Michael Hughes¹, Graham Dinsdale², Aayushi Agnihotri³, Joanne Manning², Muditha Samaranayaka⁴, Jonathan Harris² and Ariane Herrick⁵, ¹The University of Manchester, Manchester, England, United Kingdom, ²Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Salford Royal Hospital, Salford, United Kingdom, ⁵The University of Manchester, UK, Aberdeen, United Kingdom
Background/Purpose: Acro-osteolysis (A-O, terminal tuft digit resorption) is characteristic of systemic sclerosis (SSc), occurring in 20-25% of patients (1). Outcome measures are much needed. Following…
Abstract Number: 1861 • ACR Convergence 2025
Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Brecca Miller¹, Shervin Assassi², Maureen Mayes³, alejandro Molina⁴, Kelly Ruggles⁵, David Beck⁶ and Meng Zhang⁷, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine, Brooklyn, NY, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³UT Health Houston Division of Rheumatology, Houston, TX, ⁴Georgia Institute of Technology, Atlanta, GA, ⁵NYU Grossman School of Medicine, Brooklyn, NY, ⁶Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ⁷UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, vasculopathy, autoantibody presence, and high mortality in its diffuse subtype with limited effective…
Abstract Number: 1214 • ACR Convergence 2025
Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis
Sangmee Bae¹, Srijana Davuluri², Brian Lee³, Sean Lim⁴, Daniela Markovic⁵, Lorinda Chung², David Fiorentino⁶ and Christina Charles-Schoeman⁷, ¹UCLA Rheumatology, Los Angeles, CA, ²Stanford University, Stanford, CA, ³Stanford University, Stanford, ⁴Stanford University, Palo Alto, ⁵UCLA, Los Angeles, ⁶Department of Dermatology, Stanford University Medical Center, Stanford, CA, ⁷UCLA Medical Center, Santa Monica, CA
Background/Purpose: Calcinosis is a feature seen in systemic sclerosis (SSc) and dermatomyositis (DM) that leads to significant morbidity and poor quality of life. Inflammatory vasculopathy…
Abstract Number: 0692 • ACR Convergence 2025
A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
Christopher Denton¹, Philip Yee², medha kanitkar³, Charlotte Clarke⁴, Saiam Ahmed⁴, Voon H. Ong³, Francesco Del Galdo⁵, John Pauling⁶, Marina Anderson⁷, Muditha Samaranayaka⁸, Michael Hughes⁹, Smita Bhat¹⁰, Bridget Griffiths¹¹, MAYA BUCH¹², David D'Cruz¹³, Ariane Herrick¹⁴, Madelon Vonk¹⁵, Nicholas Feemantle⁴ and Dehbi Hakim-Moulay⁴, ¹University College London, UK, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶North Bristol NHS Trust, Bristol, United Kingdom, ⁷Lancaster University and NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom, ⁸Salford Royal Hospital, Salford, United Kingdom, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁰Ninewells Hospital Dundee, Dundee, Scotland, United Kingdom, ¹¹Ninewells Hospital Dundee, Newcastle, England, United Kingdom, ¹²UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹³Kings College London, London, United Kingdom, ¹⁴The University of Manchester, UK, Aberdeen, United Kingdom, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Mycophenolate mofetil (MMF) is recommended for skin in diffuse cutaneous (dc)SSc, and for lung fibrosis in SSc, but patients with limited cutaneous (lc)SSc are…
Abstract Number: 2491 • ACR Convergence 2025
High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Marina Dueñas-Ochoa¹, Cristina Valero², Francisco Morandeira³, Juan Carlos Sáez¹, Maryia Nikitsina⁴, Montserrat Roig Kim⁵, Laia De Daniel Bisbe⁵, Esther Vicente-Rabaneda⁶, Arantza Alfranca¹, Miguel A. González-Gay⁷, Martí Aguilar Coll⁸, Rosario Garcia Vicuña⁶, Javier Narváez⁹ and Santos Castañeda¹⁰, ¹Hospital La Princesa, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ⁵Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁸Hospital Bellvitge, Barcelona, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…
Abstract Number: 1858 • ACR Convergence 2025
Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.
Aurélien Chepy¹, Marie-Elise Martel¹, Solange Vivier¹, Meryem Tardivel², Antonino Bongiovanni², Marie Mistretta¹, Maxime Secq¹, Lucile Guilbert³, Eric HACHULLA⁴, Sylvain Dubucquoi⁵, David Launay¹ and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, ²Univ. Lille, BioImaging Center Lille-Nord de France (BICeL), Lille, France., Lille, France, ³CHU Lille, Institut d'Immunologie, Lille, France., Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, ⁵Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France
Background/Purpose: Antinuclear autoantibodies (ANA) are robust biomarkers for the diagnosis and prognosis of systemic sclerosis (SSc), but their role in pathogenesis is still uncertain. Recent…
Abstract Number: 1037 • ACR Convergence 2025
Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Zixing Liu¹, Adrianne Woods², Julie Paik², Laura Hummers², Scott Zeger¹, Ami Shah² and Ji Soo Kim³, ¹Johns Hopkins Biostatistics, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD, ³Johns Hopkins, Baltimore, MD
Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
Abstract Number: 0691 • ACR Convergence 2025
Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis
Brian Lee¹, Shufeng Li¹, Srijana Davuluri², Jennifer Lee¹ and Lorinda Chung², ¹Stanford University, Stanford, ²Stanford University, Stanford, CA
Background/Purpose: Elevated acute phase reactants such as platelets and C-reactive protein (CRP) have been used as inclusion criteria to enrich systemic sclerosis (SSc) clinical trials…
Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Francesco Bonomi¹, Cosimo Bruni², Silvia Laura Bosello³, Fabio Cacciapaglia⁴, Corrado Campochiaro⁵, Roberto Caporali⁶, Veronica Codullo⁷, Maria Antonietta D'Agostino⁸, Lorenzo Dagna⁹, Rossella De Angelis¹⁰, Giacomo de Luca¹¹, Dilia Giuggioli¹², Serena Guiducci¹³, Florenzo Iannone¹⁴, Francesca Ingegnoli¹⁵, Carlomaurizio Montecucco⁷, Valeria Riccieri¹⁶, Clodoveo Ferri¹⁷, Marco Matucci-Cerinic¹⁸ and Silvia Bellando Randone¹⁹, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²University of Zurich, Zurich, Switzerland, ³Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, ⁴Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷Policlinico San Matteo, Pavia, Pavia, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Ospedale San Raffaele, Milano, Italy, ¹⁰Polytechnic University of Marche, Ancona, Ancona, Italy, ¹¹Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ¹²Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, ¹³Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza ²⁰²³-²⁰²⁷, Università degli Studi di Milano, Milan, Italy, Milan, Italy, ¹⁶Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, ¹⁷University of Modena and Reggio Emilia, Modena, Modena, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹University of Florence, Florence, Italy
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 0997 • ACR Convergence 2025
Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
Olivia Pryor¹, Catalina Burbano², Nathaniel Bagge², Rutuja Kulkarni², Heather F. Jones², Livio Dukaj², Shoshana M.K. Bloom², Jackson Lirette², Rachel Lent², Prachi Dhanania², Nicole A. Ladd², Ryan Kritzer², Hana Husic², Shobitha Jillella², Candace R. Perullo², Jinyu Zhu², Teagan J. Parsons², Ira Jain², Rakshika Balasubramaniyam², Kenneth L. Jahan², Vivin Karthik², Alexander Cristofaro¹, Chandan K. Pavuluri², Jenna LaBelle², Laurie Barefoot², Shrikanta Chattopadhyay², Kim M. Cirelli², Mollie M. Jurewicz², Andrew P. Ferretti² and Cagan Gurer², ¹TScan Therapeutics, Waltham, ²TScan Therapeutics, Waltham, MA
Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Benjamin Chaigne¹, Alexandre bense², Frédérique Aubourg³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Gregory Pugnet⁶, Eric Hachulla⁷, Vincent Cottin⁸, Arnaud Hot⁸, bertrand Dunogue¹, Anuxcy Kanagaratnam², Sylvain Palat⁹, Alain Lescoat¹⁰, Sabine berthier¹¹, Emmanuel Chatelus¹², Sébastien Rivière¹³, David Launay¹⁴, Marie-Elise Truchetet¹⁵, Anh-Tuan Dinh-Xuan³ and Luc Mouthon¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²AP HP, Paris, France, ³Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Montpelliers, France, ⁷CHU, Lilles, France, ⁸CHU, Lyon, France, ⁹Limoges, Limoges, France, ¹⁰CHU Rennes - University Rennes, Rennes, France, ¹¹CHU, Dijon, France, ¹²Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹³AP HP, Parsi, France, ¹⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ¹⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
Abstract Number: 2478 • ACR Convergence 2025
Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients
Daniel Barnett¹, Alyssa Rosek², Yi-Chen Chen³, Alexander Cai⁴, Deren Esencan⁵, Sophia Matossian⁶, Christine Goudsmit⁷, Haley Havrilla⁸, Anwesha Sanyal⁹, Julie Sturza¹⁰, Pei-Suen Tsou⁶, Kathryn Torok⁹ and Jessica Turnier¹¹, ¹Division of Pediatric Rheumatology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁵¹. Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Ann Arbor, ⁸Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Division of Pediatric Rheumatology, CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹¹University of Michigan, Saline, MI
Background/Purpose: Vasculopathy is a central driving clinical, histopathologic and pathogenic feature of juvenile systemic scleroderma (jSSc), juvenile dermatomyositis (JDM) and juvenile scleroderma-overlap syndrome (jOverlap). While…
Abstract Number: 1590 • ACR Convergence 2025
Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients
Yuzo Ikari¹, Poulami Dey², James St. Clair³, Anna Webber⁴, Caroline Foster⁵, Yi-Chen Chen⁵, Ramadan Ali⁶, Dinesh Khanna⁷, David Fox⁸ and Pei-Suen Tsou⁷, ¹Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, ⁶University of Michigan, Ann Arobr, MI, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Michigan, Dexter, MI
Background/Purpose: Soluble CD13 (sCD13), released by the cleavage of cell surface CD13 by matrix metalloproteinase-14 (MMP14), has potent proinflammatory, angiogenic, and arthritogenic activities. The receptors…
Abstract Number: 0972 • ACR Convergence 2025
Prominent endothelial senescence in systemic sclerosis skin
Poulami Dey¹, William D Brodie², Megan N Mattichak³, Alexander Cai³, Qi Wu⁴, Johann Gudjonsson⁵, Dinesh Khanna⁵, John Varga⁵ and Pei-Suen Tsou⁵, ¹Michigan Medicine, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁴Michigan Medicine, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by extensive damage of the microvessels in multiple organs. We and others showed that endothelial cells (ECs) isolated from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].